Last reviewed · How we verify
BNT162b2 (Omi JN.1) (bnt162b2-omi-jn-1)
BNT162b2 (Omi JN.1) is a marketed drug by Pfizer Inc. for COVID-19 prevention and treatment. It has generated significant revenue of 63.6B. The drug's mechanism is not specified. BNT162b2 has undergone 1 trial and has 0 publications. It is a key player in the market. The company is likely to continue developing its pipeline. The drug's commercial significance is substantial.
At a glance
| Generic name | bnt162b2-omi-jn-1 |
|---|---|
| Sponsor | Pfizer |
| Drug class | unknown |
| Target | unknown |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention
- COVID-19 treatment
Common side effects
Drug interactions
- Warfarin
- Corticosteroids
- Live vaccines
- Interferon-alpha
- Immunosuppressants
- Thalidomide
- Bacillus Calmette-Guérin (BCG) vaccine
- Typhoid vaccine
- Influenza vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papillomavirus (HPV) vaccine
Key clinical trials
- A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 (Omi JN.1) CI brief — competitive landscape report
- BNT162b2 (Omi JN.1) updates RSS · CI watch RSS
- Pfizer portfolio CI